Immagina Biotechnology
Unlocking the Therapeutic Potential of Ribosomes

Human body cells need protein to proliferate. Ribosomes are molecular machines that constantly produce proteins, balancing the homeostasis of cellular proteins and adapt cellular life to changes in its environment. Misregulation of protein synthesis is known to be associated to many human diseases.

The analysis of ribosome function, its regulation and the translatome plays a crucial role in uncovering the details of which proteins are being actively translated in a cell at a specific time point or condition. This can help to understand molecular mechanisms of disease and devise more targeted therapeutic strategies. However, studying ribosome to determine protein synthesis requires robust, intuitive, and purpose-built technologies.

Immagina Biotechnology has developed sophisticated tools that can unlock the diagnostic and therapeutic potential of ribosomes.

“Our objective is to help researchers and biotech companies develop targeted and personalised drugs through our products,” states Massimiliano Clamer, founder and president of Immagina Biotechnology.

Immagina’s solutions, based on ribosome targeted RNA technologies, are geared toward finding answers to any ribosome-related query. It helps clinical researchers discover the molecular mechanism of translational control involved in many diseases and encrypted within ribosomes. Their breakthrough in ribosome research solves many scientist and patient needs.

Its RIBOLACE platform, for instance, allows academic institutions, biotech and pharma companies to measure newly-synthesised proteins and its RNA templates to deliver the highest level of correlation between gene expression and the proteome.

RIBOLACE is the only product in the market for active ribosome profiling, where clients can isolate active ribosomes and sequence the fragments of RNA covered by a ribosome. Researchers also use this platform to accelerate the discovery of novel therapeutic strategies for cancer and other congenital disorders.

CIRCAID and AHARIBO are Immagina’s other products used to study the translatome and the de-novo proteome. CIRCAID is used in high-quality library preparation for phospho-RNA sequencing with Illumina (PCR-based) or Oxford Nanopore platforms (PCR-free). AHARIBO helps explore quantitative relationships between transcript and protein levels, offering a reliable and accurate approach for downstream parallel translatome analysis and proteomic analysis, empowering scientists to shed light on the functional complexity of the mammalian genome.

Immagina offers three modules for AHARIBO; RNA, protein, and western blot. Exploiting these technologies helps biotech and pharma companies make positive strides in their novel and targeted drug and biomarker discoveries.

“Our solutions focus on accuracy and simplicity so researchers can implement their ribosome profiling and translatome studies regardless of their RNA translation expertise,” says Lutz Kirchrath, PhD, director of sales and business development at Immagina.

Immagina’s team of proficient scientists, with a strong background in RNA and molecular biology, acts as extended support for ribosome analysis and RNA sequencing. One of its primary goals is to facilitate customers by providing services analysing polysomes and ribosomes. The highly qualified scientists can help customers discover new drug targets or biomarkers providing scientific support, wet lab services and data analysis. Through advisory services, the team assists clients in adopting reliable products that can help in their research.

It plans to expand aggressively geographically and organically. Immagina wants to forge a path toward an increased understanding of ribosome function, translational control and the impact of translatome disease pathways, ultimately yielding new products and biomarker targets for disease therapies.